BIOSCEPTRE INTERNATIONAL LIMITED
Get an alert when BIOSCEPTRE INTERNATIONAL LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2027-03-31 (in 10mo)
Last filed for 2025-06-30
Confirmation statement due
2026-10-25 (in 5mo)
Last made up 2025-10-11
Watchouts
Cash
£25K
-97.2% vs 2024
Net assets
-£722K
-130.1% vs 2024
Employees
14
0% vs 2024
Profit before tax
-£4M
-51.7% vs 2024
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
We draw attention to Note 2.2 in the financial statements, which indicates that the Group has incurred a loss for the year of £4,288,666 and had net current liabilities of £4,265,448, and is expecting future losses. Current cash at bank and in hand is insufficient to fund forecast net expenditure including ongoing reasearch and development activities, and therefore additional funding will be required by the Group and the Company in the foreseeable future, being a period of at least 12 months from the date of approval of these financial statements. As stated in Note 2.2, these events or conditions, along with the other matters as set forth in Note 2.2, indicate that a material uncertainty exists that may cast significant doubt on the Group's and the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2025-06-30
| Metric | Trend | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | -£2,601,557 | -£3,947,748 | |
| Profit before tax | -£2,826,982 | -£4,288,666 | |
| Net profit | -£2,826,982 | -£4,288,666 | |
| Cash | £897,922 | £25,281 | |
| Total assets less current liabilities | £3,346,593 | -£722,040 | |
| Net assets | £2,399,813 | -£722,040 | |
| Equity | £2,399,813 | -£722,040 | |
| Average employees | 14 | 14 | |
| Wages | £1,359,300 | £1,462,671 | |
| Directors' remuneration | £627,890 | £399,167 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2024 → FY2025 · period ending 2025-06-30 vs 2024-06-30
-
Turnover
—
Not reported
-
Cash
-97.2%
£897,922 £25,281
-
Net assets
-130.1%
£2,399,813 -£722,040
-
Employees
0%
14 14
-
Operating profit
-51.7%
-£2,601,557 -£3,947,748
-
Profit before tax
-51.7%
-£2,826,982 -£4,288,666
-
Wages
+7.6%
£1,359,300 £1,462,671
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Return on capital employed | -77.7% | 546.7% | |
| Gearing (liabilities / total assets) | 67.6% | 113.4% | |
| Current ratio | 0.52x | 0.16x | |
| Interest cover | -11.18x | -11.52x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- PEM Audit Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“We draw attention to Note 2.2 in the financial statements, which indicates that the Group has incurred a loss for the year of £4,288,666 and had net current liabilities of £4,265,448, and is expecting future losses. Current cash at bank and in hand is insufficient to fund forecast net expenditure including ongoing reasearch and development activities, and therefore additional funding will be required by the Group and the Company in the foreseeable future, being a period of at least 12 months from the date of approval of these financial statements. As stated in Note 2.2, these events or conditions, along with the other matters as set forth in Note 2.2, indicate that a material uncertainty exists that may cast significant doubt on the Group's and the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.”
Group structure
- BIOSCEPTRE INTERNATIONAL LIMITED · parent
- Biosceptre (UK) Limited 100%
- Biosceptre (Aust) Pty Limited 100%
- Biosceptre ME DMCC 100%
Significant events
- “On 25 September 2025 the Company issued 40,421,808 Ordinary Shares for a consideration of £8.1m of which £4.2m has been utilised to repays loans held by the Company and the Group at the year end.”
- “Additionally, on 10 July 2025, the Group signed a lease extension on their Sydney Offices to 30 August 2028 amounting to AUD $115,540 per annum.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 10 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CURRIE, Peter Gavin | Director | 2013-10-11 | Jul 1967 | Australian |
| LOVETT, Michael John | Director | 2014-02-21 | Jul 1955 | British |
| WALTON-GREEN, Andrew John Scott | Director | 2014-10-15 | May 1963 | British |
| WOOD, Colin | Director | 2023-05-15 | May 1968 | British |
Show 10 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| AXON, Paul | Director | 2014-12-16 | 2022-03-18 |
| CAPLICE, Terrence Joseph | Director | 2014-02-21 | 2016-03-02 |
| COLLINS, Jonathan Sedgewick | Director | 2014-12-10 | 2022-03-18 |
| GIDLEY BAIRD, Alasdair Angus, Dr | Director | 2014-02-21 | 2016-04-07 |
| GUNATILLEKE, Ivan | Director | 2013-10-11 | 2014-11-27 |
| MOULDER, Kevin, Dr | Director | 2013-10-11 | 2014-10-16 |
| NEWTON, Peter John | Director | 2014-02-21 | 2016-11-23 |
| SCHLEGEL, Patrick, Dr | Director | 2020-12-17 | 2023-11-28 |
| WATTS, Ronald Stafford, Dr | Director | 2014-02-21 | 2020-11-26 |
| WINTER, Gregory Paul, Sir | Director | 2016-04-27 | 2018-11-30 |
Ownership
Persons with significant control
Filing timeline
Last 20 of 152 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-01-27 | CH01 | officers | Change person director company with change date | |
| 2025-12-20 | SH01 | capital | Capital allotment shares | |
| 2025-11-24 | AA | accounts | Accounts with accounts type group | |
| 2025-11-03 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-10-28 | CH01 | officers | Change person director company with change date | |
| 2025-10-21 | SH01 | capital | Capital allotment shares | |
| 2025-09-16 | CH01 | officers | Change person director company with change date | |
| 2025-02-12 | AA | accounts | Accounts with accounts type group | |
| 2024-10-23 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-08-20 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-07-30 | AA | accounts | Accounts with accounts type group | |
| 2024-07-10 | SH01 | capital | Capital allotment shares | |
| 2024-05-15 | SH01 | capital | Capital allotment shares | |
| 2024-04-13 | SH01 | capital | Capital allotment shares | |
| 2024-04-04 | SH01 | capital | Capital allotment shares | |
| 2024-01-23 | SH01 | capital | Capital allotment shares | |
| 2023-12-01 | TM01 | officers | Termination director company with name termination date | |
| 2023-10-23 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-10-23 | SH01 | capital | Capital allotment shares | |
| 2023-10-23 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 7
- Capital events
- 4
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.